Authors

David Mulder

Counsel

Read More

Christian Dekoninck

Partner

Read More

Adrian Toutoungi

Partner

Read More

Dr. Anja Lunze, LL.M.

Partner

Read More

Dr. Angela Knierim

Salary Partner

Read More
Authors

David Mulder

Counsel

Read More

Christian Dekoninck

Partner

Read More

Adrian Toutoungi

Partner

Read More

Dr. Anja Lunze, LL.M.

Partner

Read More

Dr. Angela Knierim

Salary Partner

Read More

23 November 2020

Pharmaceutical patent law – 2 of 2 Insights

Pharmaceutical patent law in times of crisis: A comparative study – Part 2

  • Quick read

Which extraordinary regulations have been put in place for speeding up clinical trials in emergency situations like the current coronavirus pandemic? And how is early access to new medicines warranted under such circumstance?

The second part of the two-part series ‘Pharmaceutical Patent Law in Times of Crisis: A Comparative Study’, written for the European Intellectual Property Review by our international team, addresses these questions and more on both a broad, European level and from the perspective of six national jurisdictions.
 

Read the article here

In this series

Patents & innovation

Pharmaceutical patent law in times of crisis: A comparative study – Part 1

9 November 2020

by Multiple authors

Patents & innovation

Pharmaceutical patent law in times of crisis: A comparative study – Part 2

23 November 2020

by Multiple authors

Call To Action Arrow Image

Latest insights in your inbox

Subscribe to newsletters on topics relevant to you.

Subscribe
Subscribe

Related Insights

Blue Robotic Arm
Life sciences & healthcare

Is it 'unfair' for a university to own student-created IP? Reflections on OUI v ONI

21 March 2023

by Adrian Toutoungi and Lauren Mounteney

Click here to find out more
Paper craft brain on light blue background
UPC

It is time to think about UPC opt-out again: what opt-out does

Part 1

17 January 2022
In-depth analysis

by multiple authors

Click here to find out more
Paper craft brain on light blue background
UPC

It is time to think about UPC opt-out again: how it is achieved and its strategic implications

Part 2

17 January 2022
In-depth analysis

by multiple authors

Click here to find out more